NPPB and hydrops fetalis: In some series of patients with HF (22% with concomitant T2D), the more recently developed biomarker MR-proANP has outperformed the extensively studied biomarker NT-proBNP in the prediction of mortality, [19] and some data indicate that MR-proANP may be more sensitive and specific than NT-proBNP in diagnosing HFpEF [20].